About us
Research Library
Company Pages
Allergy Therapeutics
ANGLE
Arecor Therapeutics
Avacta
Futura Medical
HUTCHMED
Redx Pharma
Scancell
Contact us
More Company News
HUTCHMED
Submission of fruquintinib Japan NDA in mCRC
29 Sep 2023
Read More
HUTCHMED
Presentation of results from the Phase IIIb trial of savolitinib at WCLC 2023
12 Sep 2023
Read More
HUTCHMED
Completion of enrollment in tazemetostat China bridging study in r/r FL
12 Sep 2023
Read More
HUTCHMED
BTD granted in China for savolitinib in Gastric Cancer
29 Aug 2023
Read More
HUTCHMED
Sovleplenib ITP Phase III met primary endpoint in China
21 Aug 2023
Read More
HUTCHMED
H123 interim results & business update
31 Jul 2023
Read More
HUTCHMED
China BTD for fruquintinib combo in advanced endometrial cancer
20 Jul 2023
Read More
HUTCHMED
Start of HMPL-415 Phase I study in China
10 Jul 2023
Read More
HUTCHMED
Phase III FRESCO-2 results published in The Lancet
16 Jun 2023
Read More
HUTCHMED
Fruquintinib MAA accepted by EMA for mCRC
15 Jun 2023
Read More
1
2
3
4
…
16
Return to HUTCHMED
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).
About us
Research Library
Company Pages
â–¼
Allergy Therapeutics
ANGLE
Arecor Therapeutics
Avacta
Futura Medical
HUTCHMED
Redx Pharma
Scancell
Contact us